Suppr超能文献

响应干细胞因子,细胞周期的G0/G1期快速退出赋予脐带血CD34+细胞增强的体外扩增潜能。

Rapid exit from G0/G1 phases of cell cycle in response to stem cell factor confers on umbilical cord blood CD34+ cells an enhanced ex vivo expansion potential.

作者信息

Traycoff C M, Abboud M R, Laver J, Clapp D W, Srour E F

机构信息

Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis 46202-5121.

出版信息

Exp Hematol. 1994 Dec;22(13):1264-72.

PMID:7525328
Abstract

Currently, the most commonly used grafts of progenitor and stem cells for patients undergoing bone marrow transplantation (BMT) are derived from large collections of autologous or allogeneic adult human bone marrow (BM). The feasibility of using human umbilical cord blood (HUCB), normal peripheral blood (PB), and smaller collections of BM as sources of hematopoietic stem cell grafts for adult patients remains questionable. We investigated the ex vivo proliferative potential of HUCB CD34+ cells as a means of expanding HUCB grafts, thereby making them more acceptable for clinical transplantation. HUCB-derived CD34+HLA-DR+ cells, maintained for 5 days in suspension cultures supplemented with 10% HUCB plasma and a combination of stem cell factor (SCF) and interleukin-3 (IL-3), displayed a 10-fold increase in the total number of CD34+ cells. In contrast, only a four-fold increase was observed in identical cultures initiated with BM-derived CD34+HLA-DR+ cells. Whereas BM CD34+ cells failed to proliferate in response to SCF alone, HUCB CD34+ cells expanded 5.6-fold by day 5, thus demonstrating an enhanced response to SCF. When the effects of SCF on the exit of HUCB cells from G0/G1 phases of cell cycle were investigated, we found that although HUCB CD34+HLA-DR+ cells were more quiescent than BM CD34+HLA-DR+ and BM CD34+HLA-DR- cells (97.5% of HUCB CD34+HLA-DR+ in G0/G1 vs. 88.6% of BM CD34+HLA-DR+ and 92.0% of BM CD34+HLA-DR- [p < 0.005]), HUCB CD34+HLA-DR+ cells exited from dormancy more rapidly than BM cells, such that by 36 to 48 hours following exposure to SCF, only 55% remained in G0/G1. Furthermore, an 8.4-fold increase in the number of HUCB CD34+ cells still residing in G0/G1 was observed on day 5 in cultures supplemented with SCF and IL-3, suggesting the generation of large numbers of primitive hematopoietic progenitor cells (HPC) in vitro. When the contribution of HUCB plasma to the exist of HUCB CD34+HLA-DR+ cells from G0/G1 phases of cell cycle was investigated, it was found that in serum-free media supplemented with only SCF or IL-3, HUCB cells did not exist G0/G1 as rapidly as when HUCB plasma or SCF plus IL-3 was present. In contrast, when HUCB plasma was added to any cytokine combination, it did not enhance the exist of BM CD34+HLA-DR+ cells from G0/G1 phases of cell cycle.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

目前,对于接受骨髓移植(BMT)的患者,最常用的祖细胞和干细胞移植物来源于大量自体或异体成人骨髓(BM)。将人脐带血(HUCB)、正常外周血(PB)以及少量骨髓作为成年患者造血干细胞移植物来源的可行性仍存在疑问。我们研究了HUCB CD34+细胞的体外增殖潜力,以此作为扩大HUCB移植物的一种手段,从而使其更适合临床移植。在补充有10% HUCB血浆以及干细胞因子(SCF)和白细胞介素-3(IL-3)组合的悬浮培养中维持5天的HUCB来源的CD34+HLA-DR+细胞,CD34+细胞总数增加了10倍。相比之下,用BM来源的CD34+HLA-DR+细胞起始的相同培养物中仅观察到4倍的增加。虽然BM CD34+细胞单独对SCF无增殖反应,但HUCB CD34+细胞到第5天扩增了5.6倍,从而证明对SCF的反应增强。当研究SCF对HUCB细胞从细胞周期G0/G1期退出的影响时,我们发现尽管HUCB CD34+HLA-DR+细胞比BM CD34+HLA-DR+和BM CD34+HLA-DR-细胞更静止(HUCB CD34+HLA-DR+中97.5%处于G0/G1期,而BM CD34+HLA-DR+中为88.6%,BM CD34+HLA-DR-中为92.0%[p<0.005]),但HUCB CD34+HLA-DR+细胞比BM细胞更快地从休眠中退出,以至于在暴露于SCF后36至48小时,只有55%的细胞仍处于G0/G1期。此外,在补充有SCF和IL-3的培养物中,第5天仍处于G0/G1期的HUCB CD34+细胞数量增加了8.4倍,表明在体外产生了大量原始造血祖细胞(HPC)。当研究HUCB血浆对HUCB CD34+HLA-DR+细胞从细胞周期G0/G1期退出的作用时,发现在仅补充SCF或IL-3的无血清培养基中,HUCB细胞从G0/G1期退出的速度不如存在HUCB血浆或SCF加IL-3时快。相反,当将HUCB血浆添加到任何细胞因子组合中时,它并未增强BM CD34+HLA-DR+细胞从细胞周期G0/G1期的退出。(摘要截断于400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验